-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 28, Lingke Pharmaceutical announced that its selective JAK1 inhibitor LNK01001 for the treatment of autoimmune diseases has completed the first patient dosing in its Phase II clinical trial for Atopic Dermatitis (AD)
Atopic dermatitis is a chronic, relapsing, inflammatory skin disease that often occurs on the face, neck, and elbow fossa
(Original abridged)